PRCT vs RARE · rev $177.6M vs rev $350.0M
Procept Biorobotics Corp (PRCT) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Procept Biorobotics Corp (PRCT) is a medical devices company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported PRCT revenue for 2026-06-30 was $177.6M. Net income was -$58.5M. PRCT currently screens at market cap $1.52B.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
PRCT currently screens at market cap $1.52B. RARE currently screens at market cap $2.79B.
Not investment advice. Open the PRCT and RARE stock pages for the full models.
Not investment advice.